Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Activity of CYP3A and Genotypes of CYP3A5 and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients

NCT01110291 is registered in ClinicalTrials.gov with University of Turku as lead sponsor.

NCT NCT01110291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01110291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Activity of CYP3A and Genotypes of CYP3A5 and MDR1 as Predictors of the Clearance and Adverse Effects of Docetaxel, and the Effect of Docetaxel to CYP3A Activity in Previously Untreated Breast Cancer Patients
Lead sponsor
University of Turku
Phase
Observational
Overall status
Completed
Start date
April 30, 2003
Completion date
March 31, 2009
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

associations between genetic data and docetaxel toxicity, cyp3a phenotyping, cyp3a5 and mdr1 genotyping, docetaxel toxicity